EE04279B1 - Omeprasooli kristalne vorm - Google Patents

Omeprasooli kristalne vorm

Info

Publication number
EE04279B1
EE04279B1 EEP200100248A EEP200100248A EE04279B1 EE 04279 B1 EE04279 B1 EE 04279B1 EE P200100248 A EEP200100248 A EE P200100248A EE P200100248 A EEP200100248 A EE P200100248A EE 04279 B1 EE04279 B1 EE 04279B1
Authority
EE
Estonia
Prior art keywords
methoxy
crystalline form
methylüsulfinylü
benzimidazole
pyridinyl
Prior art date
Application number
EEP200100248A
Other languages
English (en)
Estonian (et)
Inventor
L�vqvist Karin
Noreland David
Sund�n Gunnel
Ymn Ingvar
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27543202&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE04279(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of EE200100248A publication Critical patent/EE200100248A/xx
Publication of EE04279B1 publication Critical patent/EE04279B1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
EEP200100248A 1998-11-10 1998-11-10 Omeprasooli kristalne vorm EE04279B1 (et)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
PCT/SE1998/002028 WO1999008500A2 (en) 1998-11-10 1998-11-10 New crystalline form of omeprazole
CA002363810A CA2363810A1 (en) 1998-11-10 1998-11-10 New form of omeprazole
EP98957255A EP0969819B1 (en) 1998-11-10 1998-11-10 New crystalline form of omeprazole
BR9816067-2A BR9816067A (pt) 1998-11-10 1998-11-10 Forma a de omeprazol, omeprazol, processo para a preparação da forma a de omeprazol, formulação farmacêutica, uso de omeprazol, e, método de tratamento de distúrbios gastrointestinais.
DE29823393U DE29823393U1 (de) 1998-11-10 1998-11-10 Neue kristalline Form von Omeprazol
US10/076,225 US20020156284A1 (en) 1998-11-10 2002-02-13 Crystalline form of omeprazole

Publications (2)

Publication Number Publication Date
EE200100248A EE200100248A (et) 2002-10-15
EE04279B1 true EE04279B1 (et) 2004-04-15

Family

ID=27543202

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100248A EE04279B1 (et) 1998-11-10 1998-11-10 Omeprasooli kristalne vorm

Country Status (34)

Country Link
US (3) US6150380A (xx)
EP (2) EP0969819B1 (xx)
JP (1) JP3457945B2 (xx)
CN (1) CN1347413A (xx)
AT (1) ATE233755T1 (xx)
AU (1) AU756434B2 (xx)
BR (1) BR9816067A (xx)
CA (2) CA2363810A1 (xx)
CZ (1) CZ301635B6 (xx)
DE (3) DE969819T1 (xx)
DK (2) DK0969819T3 (xx)
DZ (1) DZ2669A1 (xx)
EE (1) EE04279B1 (xx)
ES (1) ES2139559T3 (xx)
FI (1) FI3873U1 (xx)
GR (1) GR990300034T1 (xx)
HK (1) HK1024242A1 (xx)
HR (1) HRP20010281B1 (xx)
HU (1) HUP0104379A3 (xx)
IL (1) IL142703A0 (xx)
IS (1) IS2025B (xx)
MA (1) MA26574A1 (xx)
NO (1) NO320014B1 (xx)
NZ (1) NZ511377A (xx)
PL (1) PL190870B1 (xx)
PT (1) PT969819E (xx)
RU (1) RU2207339C2 (xx)
SI (1) SI0969819T1 (xx)
SK (1) SK286562B6 (xx)
TR (1) TR200101282T2 (xx)
TW (1) TW533203B (xx)
UA (1) UA72748C2 (xx)
WO (1) WO1999008500A2 (xx)
ZA (1) ZA9811174B (xx)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6699885B2 (en) 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
SI20019A (sl) 1998-07-13 2000-02-29 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Izboljšan postopek sinteze 5-metoksi -2-/(4-metoksi-3,5-dimetil-2-piridil)metil/ sulfinil-1H-benzimidazola
IL142703A (en) * 1998-11-10 2006-04-10 Astrazeneca Ab Crystalline form of omeprazole
US6262085B1 (en) * 1999-08-26 2001-07-17 Robert R. Whittle Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6262086B1 (en) * 1999-08-26 2001-07-17 Robert R. Whittle Pharmaceutical unit dosage form
US6780880B1 (en) 1999-08-26 2004-08-24 Robert R. Whittle FT-Raman spectroscopic measurement
US6750064B2 (en) * 2000-12-28 2004-06-15 S.S.C.I. Inc. Methods of screening for possible solid forms
SI20875A (sl) * 2001-04-25 2002-10-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Kristalna oblika omeprazola
US7855082B1 (en) 2001-10-31 2010-12-21 Astrazeneca Ab Raman spectroscopic method for determining the ratio of 5-methoxy and 6-methoxy isomers of omeprazole
CA2515130A1 (en) 2003-02-05 2004-08-26 Teva Pharmaceutical Industries Ltd. Method of stabilizing lansoprazole
CA2518999A1 (en) * 2003-03-12 2004-09-23 Teva Pharmaceutical Industries Ltd Crystalline and amorphous solids of pantoprazole and processes for their preparation
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US7892354B2 (en) * 2003-10-06 2011-02-22 Solvias Ag Process for the parallel detection of crystalline forms of molecular solids
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20060024362A1 (en) 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
US20060160783A1 (en) * 2004-12-30 2006-07-20 Transform Pharmaceuticals, Inc. Novel omeprazole forms and related methods
WO2006131338A2 (en) * 2005-06-08 2006-12-14 Lek Pharmaceuticals D.D. Crystalline solvate of omeprazole sodium
EP1904064A4 (en) * 2005-07-07 2009-12-02 Reddys Lab Ltd Dr OMEPRAZOLE OF FORM B
CA2624179A1 (en) * 2005-10-06 2007-04-12 Auspex Pharmaceuticals, Inc. Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties
EP2068841B1 (en) 2006-10-05 2018-09-26 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
WO2008057802A2 (en) 2006-10-27 2008-05-15 The Curators Of The University Of Missouri Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same
EA200900985A1 (ru) 2007-01-31 2009-12-30 Крка, Товарна Здравил, Д. Д., Ново Место Способ получения оптически чистого омепразола
US20090010388A1 (en) * 2007-06-06 2009-01-08 Stahly Barbara C Microplate and methods of using the same
US8018588B2 (en) * 2007-06-06 2011-09-13 Aptuit, Inc. Sample holder and sample preparation device
US20090104236A1 (en) * 2007-10-18 2009-04-23 Pharmaceutics International, Inc. Pharmaceutical solid hybrids
US20090280173A1 (en) * 2008-05-09 2009-11-12 Ishwar Chauhan Multilayer Omeprazole Tablets
US20090280175A1 (en) * 2008-05-09 2009-11-12 Ishwar Chauhan Multilayer Proton Pump Inhibitor Tablets
WO2010134099A1 (en) 2009-05-21 2010-11-25 Cadila Healthcare Limited One pot process for preparing omeprazole and related compounds
US20120220779A1 (en) * 2009-11-03 2012-08-30 Claire Frances Crawford Novel Processes
GB201001075D0 (en) * 2010-01-22 2010-03-10 Cyclacel Ltd Crystalline forms
RU2501549C1 (ru) 2012-08-30 2013-12-20 Авва Девелопмент Лтд Фармацевтическая композиция для лечения гастроэзофагеальной рефлюксной болезни
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
RU2726320C1 (ru) * 2020-02-09 2020-07-13 Федеральное государственное бюджетное образовательное учреждение высшего образования "Кемеровский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО КемГМУ) Способ определения примесных компонентов омепразола
WO2024075017A1 (en) 2022-10-04 2024-04-11 Zabirnyk Arsenii Inhibition of aortic valve calcification

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
SE8301182D0 (sv) 1983-03-04 1983-03-04 Haessle Ab Novel compounds
SE9002043D0 (sv) * 1990-06-07 1990-06-07 Astra Ab Improved method for synthesis
DE69112917T2 (de) 1990-06-15 1996-05-15 Merck & Co Inc Kristallisationsverfahren zur Verbesserung der Kristallstruktur und -grösse.
US5877192A (en) * 1993-05-28 1999-03-02 Astra Aktiebolag Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole
SE9302396D0 (sv) * 1993-07-09 1993-07-09 Ab Astra A novel compound form
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
US5714505A (en) * 1994-01-05 1998-02-03 Astra Aktiebolag Method for treatment of psoriasis, by omeprazole or related compounds
US5856493A (en) * 1995-02-06 1999-01-05 Smithkline Beecham Corporation Process for making novel form of paroxeting hydrochloride anhydrate
SE521100C2 (sv) * 1995-12-15 2003-09-30 Astra Ab Förfarande för framställning av en bensimidazolförening
TW385306B (en) 1996-11-14 2000-03-21 Takeda Chemical Industries Ltd Method for producing crystals of benzimidazole derivatives
SE510666C2 (sv) * 1996-12-20 1999-06-14 Astra Ab Nya Kristallmodifikationer
SE9704183D0 (sv) 1997-11-14 1997-11-14 Astra Ab New process

Also Published As

Publication number Publication date
RU2207339C2 (ru) 2003-06-27
NO20012286D0 (no) 2001-05-09
TW533203B (en) 2003-05-21
FIU980578U0 (fi) 1998-12-21
AU756434B2 (en) 2003-01-16
CA2284470C (en) 2002-02-26
US6150380A (en) 2000-11-21
GR990300034T1 (en) 2000-07-31
DE69811868D1 (de) 2003-04-10
EP0969819A2 (en) 2000-01-12
DE969819T1 (de) 2000-04-06
DK199900074U1 (da) 2000-02-10
US20020156284A1 (en) 2002-10-24
PL190870B1 (pl) 2006-02-28
JP2001522780A (ja) 2001-11-20
DE29823393U1 (de) 1999-05-27
EP0969819B1 (en) 2003-03-05
CZ20011611A3 (cs) 2002-01-16
JP3457945B2 (ja) 2003-10-20
HRP20010281B1 (en) 2004-04-30
IS2025B (is) 2005-08-15
TR200101282T2 (tr) 2001-11-21
NO320014B1 (no) 2005-10-10
CA2284470A1 (en) 1999-02-25
SK5452001A3 (en) 2001-11-06
WO1999008500A2 (en) 1999-02-25
UA72748C2 (en) 2005-04-15
HK1024242A1 (en) 2000-10-05
AU1355199A (en) 1999-03-08
ES2139559T1 (es) 2000-02-16
DE69811868T2 (de) 2004-03-04
HUP0104379A3 (en) 2003-01-28
SI0969819T1 (en) 2003-06-30
ZA9811174B (en) 2000-06-07
CA2363810A1 (en) 1999-02-25
WO1999008500A3 (en) 1999-07-29
MA26574A1 (fr) 2004-12-20
US6384059B1 (en) 2002-05-07
CN1347413A (zh) 2002-05-01
IS5935A (is) 2001-05-07
PT969819E (pt) 2003-06-30
HRP20010281A2 (en) 2002-06-30
BR9816067A (pt) 2001-08-07
EP1221314A1 (en) 2002-07-10
PL348247A1 (en) 2002-05-20
NO20012286L (no) 2001-07-03
DK0969819T3 (da) 2003-05-19
NZ511377A (en) 2003-04-29
ES2139559T3 (es) 2003-10-01
ATE233755T1 (de) 2003-03-15
SK286562B6 (sk) 2009-01-07
DZ2669A1 (fr) 2003-03-22
EE200100248A (et) 2002-10-15
IL142703A0 (en) 2002-03-10
CZ301635B6 (cs) 2010-05-12
HUP0104379A2 (hu) 2002-04-29
FI3873U1 (fi) 1999-03-22

Similar Documents

Publication Publication Date Title
EE04279B1 (et) Omeprasooli kristalne vorm
SE9702483D0 (sv) New compound
SE9900274D0 (sv) New compound
SE9702065D0 (sv) New compound
HUP0303928A2 (hu) Omeprazol kristályos formája, eljárás az előállítására és ezt tartalmazó gyógyszerkészítmények
MXPA05009183A (es) Polimorfos de s-omeprazol.
MY118724A (en) New crystalline form of omeprazole
YU32301A (sh) Novi kristalni oblik omeprazola

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20101231

MM4A Lapsed by not paying the annual fees

Effective date: 20121110